Rosen Law Firm Urges Checkpoint Therapeutics Investors to Secure Counsel before June Deadline

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE)—Investors who have acquired shares of Checkpoint Therapeutics, Inc. CKPT, a clinical-stage immuno-oncology biopharmaceutical company, during the period from March 10, 2021, to December 15, 2023, are being reminded by Rosen Law Firm to enlist legal counsel prior to the approaching deadline of June 4, 2024. This call to action is associated with the pending securities class action initiated against the company. Citing the protection of investor rights globally, Rosen Law Firm represents shareholders in their legal challenges pertaining to securities class actions.

Background on Checkpoint Therapeutics

Headquartered in New York, New York, Checkpoint Therapeutics, Inc. dedicates itself to the acquisition, development, and commercialization of innovative treatments aimed at addressing the needs of patients battling solid tumor cancers. With a robust focus on immuno-oncology, an area garnering significant interest within the biopharmaceutical landscape, CKPT is closely watched by investors and industry experts alike.

Details on the Securities Class Action

This notice underscores the significance of the announced deadline for a securities class action lawsuit that affects certain individuals and entities who invested in CKPT stock during the specified 'Class Period.' The Rosen Law Firm seeks to ensure that investors are sufficiently informed about the process and are able to take appropriate measures to join the class action lawsuit if they meet the eligibility criteria and have been affected by the issues identified within the suit.

Importance of Legal Representation for Investors

Rosen Law Firm's rallying call emphasizes the importance of securing proper legal representation to potentially recover investment losses due to alleged corporate misdemeanors. With a class action lawsuit being a powerful tool for investors to collectively address grievances, the firm aims to facilitate access to justice and equitable recompense for those who may have been financially impacted during their investment tenure with Checkpoint Therapeutics, Inc.

Rosen, Checkpoint, Deadline